Ansbert Gadicke Sells 42,533 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) major shareholder Ansbert Gadicke sold 42,533 shares of the firm’s stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $0.92, for a total transaction of $39,130.36. Following the completion of the sale, the insider owned 5,125,770 shares of the company’s stock, valued at $4,715,708.40. The trade was a 0.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Ansbert Gadicke also recently made the following trade(s):

• On Monday, November 24th, Ansbert Gadicke sold 88,802 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.98, for a total transaction of $87,025.96.
• On Friday, November 21st, Ansbert Gadicke sold 64,331 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.83, for a total transaction of $53,394.73.
• On Thursday, November 20th, Ansbert Gadicke sold 41,152 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.89, for a total value of $36,625.28.
• On Wednesday, November 19th, Ansbert Gadicke sold 66,324 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.94, for a total value of $62,344.56.
• On Tuesday, November 18th, Ansbert Gadicke sold 52,627 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.93, for a total value of $48,943.11.
• On Monday, November 17th, Ansbert Gadicke sold 57,061 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.95, for a total value of $54,207.95.
• On Friday, November 14th, Ansbert Gadicke sold 61,640 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.93, for a total value of $57,325.20.
• On Thursday, November 13th, Ansbert Gadicke sold 90,951 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.98, for a total value of $89,131.98.
• On Wednesday, November 12th, Ansbert Gadicke sold 40,669 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.09, for a total value of $44,329.21.
• On Tuesday, November 11th, Ansbert Gadicke sold 55,810 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.14, for a total value of $63,623.40.

Werewolf Therapeutics Stock Performance

NASDAQ HOWL opened at $0.98 on Thursday. The company has a market cap of $47.42 million, a P/E ratio of -0.60 and a beta of 0.72. The company has a fifty day simple moving average of $1.50 and a 200 day simple moving average of $1.34. The company has a current ratio of 3.87, a quick ratio of 3.87 and a debt-to-equity ratio of 0.73. Werewolf Therapeutics, Inc. has a 12-month low of $0.60 and a 12-month high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.03. Sell-side analysts predict that Werewolf Therapeutics, Inc. will post -1.56 earnings per share for the current fiscal year.

Analysts Set New Price Targets

HOWL has been the topic of several recent research reports. JMP Securities dropped their price target on shares of Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating on the stock in a research report on Thursday, August 21st. Weiss Ratings restated a “sell (d-)” rating on shares of Werewolf Therapeutics in a report on Wednesday, October 8th. Citigroup reaffirmed a “market outperform” rating on shares of Werewolf Therapeutics in a research report on Wednesday, November 12th. Zacks Research lowered Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 21st. Finally, Bank of America dropped their price objective on Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a research note on Tuesday, November 18th. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $7.75.

Institutional Trading of Werewolf Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. Susquehanna International Group LLP increased its position in shares of Werewolf Therapeutics by 16.9% during the third quarter. Susquehanna International Group LLP now owns 93,041 shares of the company’s stock valued at $183,000 after acquiring an additional 13,439 shares during the last quarter. MPM Bioimpact LLC grew its stake in Werewolf Therapeutics by 0.9% in the 1st quarter. MPM Bioimpact LLC now owns 2,408,810 shares of the company’s stock valued at $2,341,000 after purchasing an additional 20,799 shares during the period. Charles Schwab Investment Management Inc. increased its position in shares of Werewolf Therapeutics by 33.2% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 95,712 shares of the company’s stock valued at $93,000 after purchasing an additional 23,852 shares during the last quarter. MPM Asset Management LLC raised its stake in shares of Werewolf Therapeutics by 0.6% during the 1st quarter. MPM Asset Management LLC now owns 4,309,860 shares of the company’s stock worth $4,189,000 after purchasing an additional 25,688 shares during the period. Finally, Quadrature Capital Ltd bought a new stake in shares of Werewolf Therapeutics during the 2nd quarter worth $28,000. 64.84% of the stock is owned by hedge funds and other institutional investors.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.